Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-7 of 7
Keywords: Vindesine
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1994) 51 (5): 440–445.
Published Online: 30 June 2009
...-V4, SH-1-V5, SH-1-V6, SH-1-V7, and SH-1-V8 were isolated from the human esophageal cancer cell line, SH-1, by stepwise selection on exposure to increasing doses of vindesine. SH-1-VI to SH-1-V8 acquired resistance to vindesine, in a stepwise manner, from 3- to 115-fold over findings in the parental...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1995) 52 (1): 86–87.
Published Online: 30 June 2009
...G. Falkson; W. Burger Sixteen patients with histologically confirmed inoperable hepatocellular carcinoma were treated with vindesine 3 mg/m 2 i.v. weekly. Anemia, leukopenia and neuritis were documented but no severe or life-threatening toxicity was seen. There were no objective responses among...
Journal Articles
Subject Area:
Oncology
Eiji Shimizu, Takeshi Ogura, Saburo Sone, Tadashi Nakayama, Hiroyuki Doi, Yoshihiro Takishita, Hiroyasu Bando, Masaki Kobayashi, Kouichi Kimura, Haruo Sasaki, Takaki Hashimoto, Yuhji Higuchi, Ichiro Kawase
Journal:
Oncology
Oncology (1993) 50 (1): 5–9.
Published Online: 26 June 2009
... groups and treated with cisplatin (CDDP; 80 mg/m 2 on day 1) plus either vindesine (VDS; 3 mg/m 2 on days 1 and 8) or mitomycin C (MMC; 8 mg/m 2 on days 1 and 8) every 3-4 weeks. The objective response rates were 26% (10/38) for CDDP plus VDS and 32% (11/34) for CDDP plus MMC; the corresponding response...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1989) 46 (6): 357–359.
Published Online: 26 June 2009
...Alan P. Lyss; Susan L. Luedke; Lawrence Einhorn; Dan W. Luedke; Marilyn Raney 64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy. Dosage was based on investigators’ estimate of patients’ bone marrow reserve. There were 19 evaluable...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1992) 49 (1): 45–48.
Published Online: 26 June 2009
...) but not in the 4 patients treated with cisplatin plus mitomycin plus vindesine (CMV). In the BM, the recovery of CFU-GM was more retarded in patients treated with CMV relative to that seen in patients treated with PVP. The results obtained in simultaneous cultures revealed the differences between CMV and PVP...
Journal Articles
Subject Area:
Oncology
Takao Saito, Yuji Shigemitsu, Tadahiko Kinoshita, Katsuhiro Shimoda, Toshiya Abe, Akira Nakamura, Kiyone Chikuba, Michio Kobayashi
Journal:
Oncology
Oncology (1993) 50 (4): 293–297.
Published Online: 26 June 2009
... with 5,000 cGy of radiation (days 1–40) and concurrently with two courses of chemotherapy (cisplatin, vindesine and pepleomycin, days 21-26 and 49-54). Results were compared with those of 26 historical control patients, treated with radiation since 1981. Tolerance in all patients was good. The survival rate...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1983) 40 (1): 15–17.
Published Online: 11 June 2009
..., instructions or products referred to in the content or advertisements. Lymphoma, diffuse histiocytic and lymphoblastic Nude mice Heterotransplantation Cyclophosphamide Dianhydrogalactitol m-AMSA Vindesine DCNU Oncology 40: 15-17 (1983) © 1983 S. Karger AG. Basel 0030-2414/83/0401-0015 S2.75/0...